Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Integrated Neurology Services PLLC

Neither a doctor nor a teaching hospital

Research payments

$717,437

133 payments

Through program year 2025, Integrated Neurology Services PLLC is reported as receiving $717,437 in research payments, across 133 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $32,660 12
2024 Research $177,670 39
2023 Research $45,774 25
2022 Research $201,024 18
2021 Research $229,081 32
2020 Research $7,220 5
2019 Research $24,009 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $315,354 71 payments
  2. Eli Lilly and Company $174,963 7 payments
  3. Novartis Pharmaceuticals Corporation $119,561 7 payments
  4. Genentech, Inc. $85,820 15 payments
  5. EMD Serono, Inc. $16,965 27 payments
  6. Teva Pharmaceuticals USA, Inc. $4,773 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $136,007 2 payments
  2. Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor $91,073 16 payments
  3. Evaluation of Fenebrutinib in RMS Patients II $85,820 15 payments
  4. Exploring the Safety and Tolerability of Conversion to Dose Titrated Siponimod in Patients With Relapsing Forms of Multiple Sclerosis A 6 Month Open Label Multi Center Phase III B Study Expanded $85,346 3 payments
  5. Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine $49,681 13 payments
  6. A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing Forms of Multiple Sclerosis $48,674 8 payments
  7. Preventive Treatment of Migraine: Outcomes for Patients in Real-World Healthcare Systems (Triumph) $33,333 3 payments
  8. An Extension Study of ABBV-8E12 in Early Alzheimers Disease $26,316 8 payments
  9. Long Term Prospective Multinational Parallel Cohort Study Monitoring Safety in Patients With Multiple Sclerosis Newly Started With Fingolimod Once Daily Or Treated With Another Approved Disease Modifying Therapy $19,756 2 payments
  10. A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis $18,174 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record